Evidence map›Paper›PMID 39596096›Full record

ArticleInternational journal of molecular sciences2024

Discovery of Potent Benzothiazole Inhibitors of Oxidoreductase NQO2, a Target for Inflammation and Cancer.

Asma A Belgath, Aya M Emam, Joshua Taujanskas, Richard A Bryce, Sally Freeman, Ian J Stratford

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Asma A BelgathDivision of Pharmacy & Optometry, School of Health Sciences, University of Manchester, Manchester M13 9PT, UK.ORCID 0000-0002-2123-7424
Aya M EmamDivision of Pharmacy & Optometry, School of Health Sciences, University of Manchester, Manchester M13 9PT, UK.ORCID 0000-0003-2967-6461
Joshua TaujanskasDivision of Pharmacy & Optometry, School of Health Sciences, University of Manchester, Manchester M13 9PT, UK.
Richard A BryceDivision of Pharmacy & Optometry, School of Health Sciences, University of Manchester, Manchester M13 9PT, UK.
Sally FreemanDivision of Pharmacy & Optometry, School of Health Sciences, University of Manchester, Manchester M13 9PT, UK.ORCID 0000-0002-3831-9151
Ian J StratfordDivision of Pharmacy & Optometry, School of Health Sciences, University of Manchester, Manchester M13 9PT, UK.ORCID 0000-0002-5222-4765

Funding

Egyptian Ministry of Higher Education-Mission Sector and Newton-Mosharafa PhD scholarship to AEMinistry of Education Libya PhD scholarship to AB
6 · The paper itself

Abstract

Inhibitors of NQO2 (NRH: quinone oxidoreductase) have potential application in several areas of medicine and pharmacology, including cancer, neurodegeneration (PD and AD), stroke, and diabetes. Here, resveratrol, a known inhibitor of NQO2, was used as the lead by replacing the double bond in resveratrol with a benzothiazole scaffold. Fifty-five benzothiazoles were designed as NQO2 inhibitors and synthesized, comprising five benzothiazole series with 3,5-dimethoxy, 2,4-dimethoxy, 2,5-dimethoxy, 3,4-dimethoxy, and 3,4,5-trimethoxy substituents, the key synthetic step being a Jacobson cyclisation with the appropriate thiobenzamide. All compounds were evaluated in an NQO2 enzyme inhibition assay, with four compounds having IC

Indexed as

BenzothiazolesNeoplasmsQuinone ReductasesEnzyme InhibitorsHumansInflammationMolecular Docking SimulationResveratrolStructure-Activity RelationshipbenzothiazoleBenzothiazolesEnzyme InhibitorsNRH - quinone oxidoreductase2Quinone ReductasesResveratrolbenzothiazolecancerinflammationJacobsen cyclisationNQO2oxidative damage

Identifiers

PMID39596096
PMCPMC11593696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.